Navigation Links
Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
Date:12/3/2013

225 shares per $1,000 principal amount, which is equivalent to an initial conversion price of approximately $8.19 per share of common stock, and is subject to adjustment under the terms of the Notes. The initial conversion price of the Notes represents a premium of approximately 32.5% to the $6.18 per share closing price of the Company's common stock on December 2, 2013. The sale of the Notes is expected to close on December 6, 2013, subject to customary closing conditions.

The Company estimates that the net proceeds from the offering will be approximately $96.1 million after deducting the initial purchasers' discounts and commissions and the estimated offering expenses payable by it.  The Company intends to use the net proceeds from the offering of the Notes for working capital and other general corporate purposes. The Company may also use a portion of the net proceeds to in-license or acquire new businesses or products; however, the Company has no current commitments or obligations to do so.

The Notes were offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act. Neither the Notes nor the shares of Company's common stock issuable upon conversion of the Notes, if any, have been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any notes or common stock, nor shall there be any sale of notes or common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or any jurisdiction. Any offer, if at all, will be made only pursuant to Rule 144A under the Securities Act.

Forward‐Looking Statements Ore
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
2. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
3. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
6. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
7. Orexigen Therapeutics to Present at Upcoming Conferences
8. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
9. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
10. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
11. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015   Decision Resources Group ... advantages of Otezla are its oral administration, alternative ... reported by surveyed rheumatologists. Otezla was the first ... treatment of active psoriatic arthritis in ... of care includes conventional oral treatments including disease-modifying ...
(Date:7/1/2015)... 1, 2015 Isagenix International, a leading global ... Gold, three Silver, and three Bronze Stevie® Awards at ... Chicago this month.The American ... awards program in the U.S. "Winning ... in developing leaders, cultivating talent, creating a unified team, ...
(Date:7/1/2015)... 2015  UCB, a multinational biopharmaceutical company, and ... in designing, transforming, and running intelligent business operations, ... of their close collaboration in driving transformation that ... services (GBS) finance organization. The Aecus ... work together effectively to embrace the innovative promise ...
(Date:6/30/2015)... , June 30, 2015  NASA astronaut Kjell ... next month on his first mission to the International ... from 8 to 9 a.m. EDT Tuesday, July 7. ... in Star City, Russia . The interviews ... NASA Television highlighting his mission training. To schedule ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2
... the,following changes to the S&P 500 and S&P MidCap 400 indices:, ... the S&P 500 after the close of trading ... close of trading General Growth Properties had a market ... -- S&P MidCap 400 constituent Cephalon Inc. (Nasdaq: CEPH ) will ...
... presentation,today at the American Heart Association Scientific Sessions ... have presented,data from the Atherosclerosis Risk in Communities ... on chromosome 9p21,detected by the deCODE MI(TM) test ... individual risk of future coronary heart disease,(CHD). This ...
... (Nasdaq: KNDL ) a,leading, global full-service clinical ... Financial Officer Karl "Buzz",Brenkert III will participate in ... will be held at the Arizona Biltmore Resort ... is scheduled for,Friday, Nov. 14 at 10 a.m. ...
Cached Biology Technology:Standard & Poor's Announces Changes to U.S. Indices 2Standard & Poor's Announces Changes to U.S. Indices 3Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy 2Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy 3Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy 4Kendle to Present at the 2008 Credit Suisse Health Care Conference 2
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
(Date:6/23/2015)... MINNETONKA, Minn. , June 23, 2015 /PRNewswire/ ... technology company that supports the entire spectrum of ... iMedNet ™ , the company,s ... has been awarded a Silver 2015 Stevie® Award ... the Health Products & Services Website category.  The ...
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... (NTU), Singapore, aims to achieve new peaks in research ... of significance globally - synthetic biology, stem cells and ... held on 23 and 24 March 2009 that allowed ... opportunity to get to know the latest research and ...
... scientific works dealing solely with the flu virus, we ... says Klaus Schughart, head of the Experimental Mouse Genetics ... discovered that an excessive immune response is responsible for ... overreaction has genetic roots. The findings have now been ...
... Arbor, MI and Munich (Germany) March 26, 2009 ... for the analysis of Next Generation Sequencing (NGS) data, ... (MCTP) at the University of Michigan installed a Genomatix ... at its labs in Ann Arbor, MI. GMS and ...
Cached Biology News:Nanyang Technological University and University of California, Berkeley pursue research alliance 2The host makes all the difference 2MCTP bought Genomatix NextGen Sequencing analysis stations 2
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
... structurally and functionally related BMPs, which are ... originally identified as protein regulators of cartilage ... in embryogenesis and morphogenesis of various tissues ... chemotaxis and apoptosis of various cell types, ...
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
Biology Products: